Sofpironium bromide | BBI-4000 | CAS#1628106-94-4 | Anticholinergic

MedKoo Cat#: 327025 | Name: Sofpironium bromide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sofpironium, also known as BBI-4000, belongs to a class of drugs called ‘anticholinergics,’ which exert their effect by blocking the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including the activation of sweat glands. Soft-anticholinergics, such as sofpironium, exert their action topically and are rapidly metabolized into a considerably less active metabolite when they reach the blood system, thus potentially allowing for effective doses to be used while reducing the limiting systemic side effects associated with other drugs in this class.

Chemical Structure

Sofpironium bromide

CAS#1628106-94-4 (bromide)

Theoretical Analysis

MedKoo Cat#: 327025

Name: Sofpironium bromide

CAS#: 1628106-94-4 (bromide)

Chemical Formula: C22H32BrNO5

Exact Mass: 469.1464

Molecular Weight: 470.40

Elemental Analysis: C, 56.17; H, 6.86; Br, 16.99; N, 2.98; O, 17.01

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 650.00	2 Weeks
25mg	USD 1,550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1628251-49-9 (cation) 1628106-94-4 (bromide) 2409055-48-5 (tosylate)

Synonym

Sofpironium bromide; BBI-4000; BBI4000; BBI 4000

IUPAC/Chemical Name

(3R)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium bromide

InChi Key

FIAFMTCUJCWADZ-JOFREBOKSA-M

InChi Code

InChI=1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1

SMILES Code

C[N+]1(CC(OCC)=O)CC[C@@H](OC([C@@](O)(C2CCCC2)C3=CC=CC=C3)=O)C1.[Br-]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 470.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kirsch B, Smith S, Cohen J, DuBois J, Green L, Baumann L, Bhatia N, Pariser D, Liu PY, Chadha D, Walker P. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial. J Am Acad Dermatol. 2020 Jun;82(6):1321-1327. doi: 10.1016/j.jaad.2020.02.016. Epub 2020 Feb 15. PMID: 32068049. 2: Bodor M. Új lágy gyógyszerek kifejlesztése és klinikai sikere [Development and clinical success of novel soft drugs]. Orv Hetil. 2020 Mar;161(10):363-373. Hungarian. doi: 10.1556/650.2020.31657. PMID: 32115992. 3: Paik J. Sofpironium Bromide: First Approval. Drugs. 2020 Dec;80(18):1981-1986. doi: 10.1007/s40265-020-01438-1. PMID: 33236266. 4: Yokozeki H, Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, Kanda H, Kitahara H, Kinoshita M, Nakasu I, Hattori N, Horiuchi Y, Maruyama R, Mizutani H, Murakami Y, Watanabe C, Kume A, Hanafusa T, Hamaguchi M, Yoshioka A, Egami Y, Matsuo K, Matsuda T, Akamatsu M, Yorozuya T, Takayama S. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021 Mar;48(3):279-288. doi: 10.1111/1346-8138.15668. Epub 2021 Jan 7. PMID: 33410265; PMCID: PMC7986147. 5: Hobart J, Burke L, Kirsch B, Chadha D. Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax): Evaluation of Measurement Performance. J Drugs Dermatol. 2021 Apr 1;20(4):410-418. doi: 10.36849/JDD.2021.5569. PMID: 33852243. 6: Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, Kanda H, Kitahara H, Kinoshita M, Nakasu I, Hattori N, Horiuchi Y, Maruyama R, Mizutani H, Murakami Y, Watanabe C, Kume A, Hanafusa T, Hamaguchi M, Yoshioka A, Egami Y, Matsuo K, Matsuda T, Akamatsu M, Yorozuya T, Takayama S, Yokozeki H. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021 Aug;48(8):1149-1161. doi: 10.1111/1346-8138.15927. Epub 2021 May 26. PMID: 34041788; PMCID: PMC8453842. 7: Gregoriou S, Tsiogka A, Kontochristopoulos G, Offidani A, Campanati A. Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis. Expert Opin Investig Drugs. 2022 Jan;31(1):15-21. doi: 10.1080/13543784.2022.2017880. Epub 2021 Dec 22. PMID: 34890517. 8: Armstrong A, Reddy R, Chadha D, Kircik L. SUPPLEMENT ARTICLE: A Novel Drug Delivery Method: Retrometabolic Drug Design. J Drugs Dermatol. 2022 Apr 1;21(4):s5-s10. PMID: 35389593. 9: Fujimoto T, Okatsu H, Miyama H. Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2022 Jun;49(6):594-599. doi: 10.1111/1346-8138.16384. Epub 2022 Apr 8. Erratum in: J Dermatol. 2022 Aug;49(8):800. doi: 10.1111/1346-8138.16511. PMID: 35394087; PMCID: PMC9321746. 10: Kisielnicka A, Szczerkowska-Dobosz A, Purzycka-Bohdan D, Nowicki RJ. Hyperhidrosis: disease aetiology, classification and management in the light of modern treatment modalities. Postepy Dermatol Alergol. 2022 Apr;39(2):251-257. doi: 10.5114/ada.2022.115887. Epub 2022 May 9. PMID: 35645673; PMCID: PMC9131949. 11: Wong NS, Adlam TM, Potts GA, Farshchian M. Hyperhidrosis: A Review of Recent Advances in Treatment with Topical Anticholinergics. Dermatol Ther (Heidelb). 2022 Dec;12(12):2705-2714. doi: 10.1007/s13555-022-00838-3. Epub 2022 Nov 3. PMID: 36329359; PMCID: PMC9674821. 12: Amano Y, Mazda J, Amano K, Ohi K, Shioiri T. Efficacy of sofpironium bromide gel on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: double-blind, controlled crossover study. BJPsych Open. 2023 Jan 13;9(1):e14. doi: 10.1192/bjo.2022.630. PMID: 36636808; PMCID: PMC9885354. 13: Funato M, Iwata R, Iimoto M. Efficacy of 5% sofpironium bromide gel in Duchenne muscular dystrophy with palmoplantar hyperhidrosis: A retrospective case study. J Dermatol. 2024 Jan;51(1):135-139. doi: 10.1111/1346-8138.16990. Epub 2023 Oct 5. PMID: 37795807.